Navigation Links
WHO data confirms low level of resistance to Tamiflu

New data published by the World Health Organisation (WHO) has confirmed a low frequency of resistance to Tamiflu (oseltamivir) over 3 influenza seasons (2003 ?2006)1.

The information, published by the Neuraminidase Inhibitor Susceptibility Network in the WHO’s Weekly Epidemiological Record, has shown that resistance of around 0.3% to oseltamivir was seen during the influenza seasons in which there had been substantial Tamiflu use in Japan (35 million patients), the highest use in any market. This level of resistance is extremely low compared to rates of 65% seen in Japan with another antiviral, amantadine2.

"These results confirm that the potential for the development of resistance to Tamiflu is very low, even when used extensively in the management of seasonal influenza," commented Dr. David Reddy, Pandemic Task Force Leader, Roche. "This provides reassurance to the scientific community that since the introduction of Tamiflu in 1999, the levels of resistance have remained similar to those seen in the clinical development programme. Roche and the NISN continue to maintain high vigilance to keep on top of the evolving virus. "

Information gathering and results

As with any antiviral medication, there is a theoretical risk that a virus may emerge with decreased sensitivity to a drug. The Neuraminidase Inhibitor Susceptibility Network undertook screening for susceptibility to oseltamivir of influenza viruses randomly submitted to the national WHO Collaborating Centre for Reference and Research on Influenza and other Respiratory Diseases in Tokyo, Japan. Influenza virus isolates collected were tested by neuraminidase inhibition assay (IC50 or sequence analysis) to detect mutations associated with drug-resistance.

Results were as follows:

Influenza Season in Japan No of Influenza A isolates tested Resistance No of Influenza B isolates tested Resistance

2003/2004 1180 3 (0.3%) 171 0 '"/>

Source:Ketchum


Page: 1 2 3

Related biology news :

1. LUCA technologies confirms real-time methane generation
2. Ancient DNA confirms single origin of Malagasy primates
3. Updated data on novel HPV vaccine confirms efficacy in large population
4. First human study confirms that immune cells can be a primary cause of bone loss in gum disease
5. New method confirms importance of fungi in Arctic nitrogen cycle
6. New data from NIH lab confirms protocol to reverse type 1 diabetes in mice
7. Genetic surprise confirms neglected 70-year-old evolutionary hypothesis
8. Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent
9. Cornell lab confirms deadly fish virus spreading to new species
10. Unprecedented water level rise in Somalia
11. Low level of extinction during ice age linked to adaptability

Post Your Comments:
(Date:11/19/2009)...tries of the world. It is widely used for human co...It also is considered an exemplar plant species fo... genome architecture. The authors of the research ...t description of the B73 maize genome to probe som... plant biology. The ten papers consider maize cent...
(Date:11/19/2009)... multi-institutional effort co-led by three Cold S...ed today in publication of a landmark series of pa...dented detail the DNA sequence of maize ( Zea mays...rth American consumers, is one of the world,s most...al crop grown in the United States, representing $...
(Date:11/19/2009)...swire-FirstCall/ -- BIO-key International, Inc. (O...lic safety and finger-based biometric identificati...er Meeting held today was adjourned without any ac... ,, (Logo: http://www.newscom.com/cgi-bin/prnh....3% of the 35 million votes cast voted in favor of...
Breaking Biology News(10 mins):PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Finally The Round Diet 21 A Diet Simple Enough that Even a Kindergartener Can Follow It 50523 1Finally The Round Diet 21 A Diet Simple Enough that Even a Kindergartener Can Follow It 50523 2WellPoint Recovers and Saves 2475 Million Through Anti Fraud Programs and Investigations in 2008 50521 1WellPoint Recovers and Saves 2475 Million Through Anti Fraud Programs and Investigations in 2008 50521 2WellPoint Recovers and Saves 2475 Million Through Anti Fraud Programs and Investigations in 2008 50521 3Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 1Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 2Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 3Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 4Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops 50519 5
...t suffering from depression. Children take on an e...t and for other family members. It is therefore im...s and have support functions in place for the whol...This is the conclusion of a thesis from the Sahlgr... Registered Nurse Britt Hedman Ahlstrm has examin...
...daq: AWRE ), a leading supplier of broadband tec...hat its Board of Directors has approved a modified...00 shares, or approximately 15%, of its outstandin... share purchase rights), at a price in the range o...e purchase price of approximately $9.1 million. T...
...man, co-author of the study titled "Drought Sensit... of the TEAM Network at Conservation International...ing on energy security and food security, this stu...tem security in short, how nature keeps us health... problem; drying climate is just as bad or worse f...
Other Biology News:Children seriously affected when a parent suffers from depression 2Aware, Inc. Commences Dutch Auction Tender Offer 2Aware, Inc. Commences Dutch Auction Tender Offer 3Aware, Inc. Commences Dutch Auction Tender Offer 4
(Date:11/19/2009)... InSound is honored by latest award fo... Newark, CA (PRWEB) November 16, 2009 -- Popu...visible” hearing aid from InSound Medical a ...rd in the Health category.    ...ed to reside deep in the hearing canal for up to f...
(Date:11/18/2009)...y personnel need to be able to find explosive mate...em. To aid such searches, the National Institute o...om the Department of Homeland Security, has develo...eference Material (SRM) 2905, Trace Particulate Ex...ay methods, the SRM will be helpful in calibrating...
(Date:11/18/2009)... Vernier,s experience in data analysis combined wi...am kits and curricula provide state-of-the...BEAVERTON, Ore., Nov. 18 Vernier S...l science interfaces, sensors, and software and Bi...urer and distributor of life science research and ...
(Date:11/18/2009)...SISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM ...fe sciences product development company that ident...g cancer-related products at various stages of dev...uating nimotuzumab were presented today in a poste... Cancer Therapeutics conference in Boston, Massach...
Breaking Biology Technology:Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3New NIST trace explosives standard slated for homeland security duty 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...enosumab is a new drug being,studied to prevent fr...al,therapy. Results of a phase 3 clinical trial us... San Antonio Breast Cancer Symposium by Georgiana,... Denosumab is a highly specific antibody that int...zed cells that break down bone. Because it is,high...
...ontinuing Interest in Peregrine,s Anti-PS Technolo... -, TUSTIN, Calif., Dec. 14 Peregrine,Pharmaceut...pharmaceutical,company developing monoclonal antib...virus (HCV) infection, today announced the sudden ...ract award with the Defense Threat,Reduction Agenc...
...l Potential Uses, Excluding U.S. and Japan, No Ot...ase BASINGSTOKE, England and PHILADELPHIA, Decemb...Q),the global specialty biopharmaceutical company,...e rights, excluding the U.S. and Japan, to AT-1001...1 is Alba,s lead inhibitor,of barrier dysfunction ...
Other Biology Technology:New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 2Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 3Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 4Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 3
mirVana™ qRT-PCR Primer Set for Normalization (5S) from Ambion
Rabbit Anti-Human JUB Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Caspase-8 Inhibitor Z-IETD-FMK from BioVision
GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen
Biology Products: